Boehringer Ingelheim
Petition launched to raise AF and stroke awareness
April 20, 2012Business Services, Medical Communications, Sales and Marketing AF, Boehringer Ingelheim, Pradaxa, Xarelto, stroke
Various health organisations have called on more people involved in the management of atrial fibrillation (AF) to help raise awareness …
NICE recommends Pradaxa for stroke prevention
March 15, 2012Sales and Marketing Boehringer Ingelheim, NICE, Pradaxa, atrial fibrillation
NICE has given a limited recommendation to Boehringer Ingelheim’s blood thinner Pradaxa. The watchdog said in final guidance that Pradaxa …
Boehringer censured over Pradaxa website
March 8, 2012Medical Communications ABPI, Boehringer Ingelheim, PMCPA, Pradaxa
Boehringer Ingelheim has breached the ABPI’s Code of Conduct over the use of its Pradaxa website. Pradaxa is a …
Boehringer to invest €17m in Biberach, Vienna facilities
March 6, 2012Manufacturing and Production Austria, BI-HEX, Boehringer Ingelheim, Vienna, manufacturing
Boehringer Ingelheim has said it plans to invest around €17 million in its biopharmaceutical development and manufacturing capabilities at Biberach, …
Boehringer broadens afatinib studies
January 27, 2012Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, afatinib
Boehringer Ingelheim is expanding the scope of its studies into afatinib to test its use against head and neck cancers. …
Boehringer invests $65 million in early R&D centre
November 16, 2011Research and Development, Sales and Marketing Boehringer Ingelheim
Boehringer Ingelheim is investing $65 million for an early-stage research and development centre in the US. The new 72,000 sq.ft. …
Boehringer developing Facebook game
November 15, 2011Medical Communications Boehringer Ingelheim, Facebook
Boehringer Ingelheim is developing a new Facebook civilisation game in the hopes of helping the public understand the difficulty involved …
Boehringer hails hepatitis C candidate
November 9, 2011Sales and Marketing BI201335, Boehringer Ingelheim, HCV, Incivo, Victrelis, hepatitis C
Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients’ treatment time …
Once daily Viramune set for approval in Europe
August 1, 2011Sales and Marketing Boehringer Ingelheim, HIV
European regulators have recommended the approval of a new, once-daily form of Boehringer Ingelheim’s HIV treatment Viramune. Viramune (nevirapine) has …
Spiriva mist inhaler safety concerns raised
June 16, 2011Sales and Marketing Boehringer Ingelheim, Spiriva, drug safety
A mist inhaler used to deliver Spiriva to patients with chronic obstructive pulmonary disease (COPD) may be linked to an …
Boehringer-Lilly launch diabetes drug Tradjenta in US
June 16, 2011Sales and Marketing Boehringer Ingelheim, Tradjenta, diabetes, lilly
Boehringer Ingelheim and Eli Lilly’s new type II diabetes treatment Tradjenta has been launched in the US. Tradjenta (linagliptin) is …
US approval for Boehringer’s diabetes drug Tradjenta
May 3, 2011Sales and Marketing Boehringer Ingelheim, Tradjenta, diabetes, lilly
Tradjenta, the once-daily oral type II diabetes treatment developed by Boehringer Ingelheim, has been approved by US regulators. The FDA …
Boehringer begins late-stage hep C trial
April 27, 2011Research and Development BI 201335, Boehringer Ingelheim, hepatitis C
Boehringer Ingelheim has begun enrolling patients in North America for a phase III trial of its chronic hepatitis C virus …
Digital Pharma: Boehringer UK tweets politicians with afib message
April 21, 2011Medical Communications Boehringer Ingelheim, Digital Pharma blog, Twitter, medical communications
Boehringer Ingelheim UK is using Twitter to reach politicians with local disease awareness messages. About a third of MPs have …
Boehringer’s Pradaxa recommended for expanded European licence
April 18, 2011Sales and Marketing Boehringer Ingelheim, CHMP, Pradaxa
Pradaxa is on course to expand its European licence with a recommendation from the CHMP for a new indication in …
Latest content
The evidence bar impacting UK medical cannabis access
Addressing the rheumatic disease diagnostic gap in primary care
